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Abstract
Latshang, Tsogyal D. and Konrad E. Bloch. How to treat patients with obstructive sleep apnea syndrome during
an altitude sojourn. High Alt. Med. Biol. 12:303-307.—Considering the high prevalence of the obstructive sleep
apnea syndrome (OSA), it is expected that many patients with the disorder are traveling to altitude. However,
this may expose them to the risk of pronounced hypoxemia, exacerbation of nocturnal breathing disturbances by
frequent central apneas, impaired daytime performance, and high blood pressure. Recently, randomized studies
specifically investigated the effects of altitude (1630–2590 m) in OSA patients and the optimal treatment in this
setting. The results indicate that patients should continue to use continuous positive airway pressure therapy
(CPAP) when sleeping at altitude. Since CPAP alone does not control central sleep apnea emerging at altitude,
combined treatment with acetazolamide and CPAP should be considered, in particular, in patients with severe
OSA and co-morbidities. Supplemental oxygen combined with CPAP might be advantageous in patients with
OSA and concomitant cardiopulmonary disease by preventing hypoxemia and central sleep apnea. In patients
unable to use CPAP or if electrical power is not available, an optimally fitted mandibular advancement device
might be an alternative treatment option that can be combined with acetazolamide during altitude sojourns.
Acetazolamide alone is also beneficial and better than no treatment at all, since it improves oxygen saturation,
breathing disturbances, and the excessive blood pressure elevation in OSA patients traveling to altitude.
Key Words: obstructive sleep apnea; continuous positive airway pressure; acetazolamide; treatment; hypoxia;
altitude
Introduction
Considering the high prevalence of obstructivesleep apnea (OSA) of at least 3%–7% in adult men and
2%–5% in adult women, many patients are expected to travel
to the mountains. It is therefore surprising that relatively few
studies specifically addressing the health effects of altitude
exposure in OSA patients have been performed. After a brief
review of OSA in general, we will discuss the available sci-
entific data on OSA at altitude and give recommendations on
pre-travel evaluation and treatment at altitude.
The main manifestations of OSA comprise excessive
sleepiness, impaired concentration, unrefreshing sleep with
habitual snoring, and witnessed apneas (McNicholas, 2008).
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OSA represents a risk factor for traffic accidents and cardio-
vascular disease (Bradley and Floras, 2009). The diagnosis is
suspected on clinical grounds and confirmed by a sleep study
(McNicholas, 2008). The main treatment is nocturnal contin-
uous positive pressure (CPAP) applied through a nasal or
oral-nasal mask (Gordon and Sanders, 2005). CPAP splints
the upper airway, thereby preventing airway occlusion with
apneas, oxygen desaturation, and sleep disruption. Daytime
symptoms usually diminish within a few days. Alternatives to
CPAP include mandibular advancement devices (MAD) and
surgery in selected cases (Randerath et al., 2011). Weight loss
in obese patients and avoidance of alcohol and smoking are
important adjuncts (Ryan, 2005).
OSA Patients at Altitude
Physiological consequences
Prompted by the observation that occasional obstructive
apneas in healthy trekkers ascending to 5050 m in Nepal
disappeared with increasing altitude while frequent central
apneas/hypopneas emerged, Burgess and colleagues studied
effects of altitude exposure in 5 men with OSA (Burgess et al.,
2004). During sleep studies in normobaric hypoxia simulating
an altitude of 2750 m, obstructive apneas were replaced by
central sleep apneas (Burgess et al., 2006). Patz and colleagues
reported on 11 OSA patients living at > 2400 m evaluated by
polysomnography at home, in a sleep laboratory at 1370 m,
and (in 5 of the 11 patients) near sea level (Patz et al., 2006).
Altitude descent resulted in a significant decrease in sleep-
related breathing disturbances due to a decrease in hy-
popneas and central apneas. In order to corroborate these
findings, we performed a randomized cross-over trial in
34 OSA patients studied during a few days off CPAP at
490 m, 1860 m, and 2590 m, respectively, in the Swiss Alps
(Nussbaumer-Ochsner et al., 2010). Altitude exposure in-
duced pronounced hypoxemia and increased sleep-related
breathing disturbances due to frequent central apneas/
hypopneas (Fig. 1). Daytime evaluation at altitude revealed
that the patients performed poorly in driving simulator tests,
had increased blood pressure, cardiac arrhythmias, weight
gain, and leg edema suggesting water retention (Nussbau-
mer-Ochsner et al., 2010). These data suggested unfavorable
health effects of altitude in untreated OSA patients. Since
cardiovascular diseases and diabetes are common in OSA
patients and since altitude worsens intermittently and im-
poses sustained hypoxemia, the resulting excessive sympa-
thetic activation may expose patients to a high risk of adverse
cardiovascular events at altitude.
Treatment of OSA at altitude
We recently performed a randomized, placebo-controlled,
double-blind trial evaluating acetazolamide as a treatment for
OSA at altitude (Nussbaumer-Ochsner et al., 2011). The study
confirmed that acetazolamide (250 mg twice a day) signifi-
cantly improved nocturnal oxygen saturation, reduced cen-
tral apneas/hypopneas and sleep disturbances at 1860 m and
2590 m, when compared to no treatment at all (Nussbaumer-
Ochsner et al., 2011). In addition, acetazolamide prevented
excessive blood pressure rise and weight gain. However, a
considerable amount of obstructive apneas/hypopneas per-
sisted. Thus, acetazolamide provides some benefit but is not
an optimal treatment for OSA at altitude. Nevertheless, it
might be a valuable option if CPAP therapy is not feasible.
In a subsequent randomized, placebo-controlled, double-
blind study we evaluated whether combined treatment with
acetazolamide and CPAP was superior to CPAP alone (Lat-
shang et al., 2010). Fifty-one OSA patients living below 800 m
were studied during a sojourn of a few days in a Swiss alpine
village at 1630 m and 2590 m, respectively. On combined
treatment with CPAP (RemStar M-series, Philips Respironics,
Andover, MA) and acetazolamide (250 mg in the morning and
500 mg in the evening), the apnea/hypopnea index (AHI) was
normalized at both moderate altitudes. On CPAP alone, re-
sidual central apneas persisted. CPAP devices were operated in
the automatic mode with a pressure range of 5–15 cm H2O. The
applied pressure at 2590 m exceeded values at 490 m by 2 cm
H2O if acetazolamide was not used; on combined autoCPAP
and acetazolamide treatment, no difference in mask pressure
between values at 2590 m and 490 m was noted. The data from
this study suggest that the combined treatment seems to be
appropriate for OSA patients at moderate altitude.
FIG. 1. In patients with OSA syndrome studied at 490 m, 1860 m, and 2590 m, respectively, during a few days of CPAP
withdrawal, altitude exposure was associated with a significant increase in the total AHI (represented by the total length of
the horizontal bars). The increase was related to emergence of frequent central apneas/hypopneas (represented by bars to the
right) while obstructive apneas/hypopneas changed little (bars to the left). Bars and lines are medians and quartile ranges
from data in 34 patients reported by Nussbaumer-Ochsner et al. (2010).
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Theophylline has been shown to improve high altitude
periodic breathing in healthy subjects (Fischer et al., 2004) but
it is not an effective therapy for OSA and has the drawback of
being arrhythmogenic and sleep disturbing. Modafinil is a
stimulant that improves reaction time and subjective sleepi-
ness in OSA patients during a few days of CPAP withdrawal
(Williams et al., 2010). It might be of some use in very special
circumstances when a patient is unable to use an effective
OSA therapy but needs to maintain a high level of alertness.
Since modafinil does not improve nocturnal breathing and
oxygenation and considering its potential to trigger cardio-
vascular events, it is not generally recommended, in particular
not in hypoxic conditions.
Custom-fitted mandibular advancement devices (MAD)
improve sleep-related breathing disturbances, daytime
symptoms, and vigilance in OSA patients at low altitude (Fig.
2) (Bloch et al., 2003; Randerath et al., 2011). Studies at altitude
have not been performed so far but MAD seem to be prom-
ising for persons traveling frequently to the mountains and
ready to make the effort of getting a custom-fitted appliance.
It usually takes several weeks to fabricate a MAD and become
accustomed to its use. Efficacy should be verified prior to
travel with a sleep study, wearing the dental device for at least
4 days. This treatment can therefore not be established within
short time before departing to high altitude. Prefabricated
devices can be purchased at a lower cost than custom-fitted
appliances, but they are less effective and therefore not re-
commended (Vanderveken et al., 2008).
A nasal expiratory pressure device (Provent) consisting of
valves inserted into the nares has been shown to improve OSA
in highly selected patients (Berry et al., 2011). Further studies
are required to evaluate whether Provent works at altitude.
Nasal obstruction due to dry air at altitude might be a problem
with this therapy. In OSA patients with coexistent chronic
rhinitis, nasal decongestants (during an altitude sojourn of a
few days) or topical steroids might be useful adjuncts that
contribute to a better sleep quality and might also slightly im-
prove OSA (Clarenbach et al., 2008; Kohler et al., 2009).
Surgical interventions have a limited role in the treatment
of OSA and cannot be recommended in general. In particular,
the effects of soft tissue surgery on snoring and OSA are un-
predictable and might not persistent (Ryan, 2005).
Recommendations for OSA Patients
Traveling to Altitude
Pre-travel considerations and preparation
Depending on the time until departure, the destination and
duration of the planned travel, the sleeping altitude, the
available infrastructure (electricity), co-morbidities, age, and
other individual factors, preparations may vary consider-
ably (Nussbaumer-Ochsner and Bloch, 2007; Nussbaumer-
Ochsner and Bloch, 2010). General recommendations include
sufficient and regular sleep, and avoidance of alcohol, sedatives,
sleeping pills, and smoking. Concomitant illness such as car-
diovascular disease, diabetes, and obstructive airway disease
should be controlled and stable. Specific recommendations re-
garding diseases other than OSA have been reported elsewhere
and are not further discussed (Dehnert and Bartsch, 2010; Luks
and Swenson, 2007; Nussbaumer-Ochsner and Bloch, 2010).
Patients should have sufficient supply of their regular medica-
tion and a reserve for emergencies. Counseling regarding sus-
ceptibility to, prevention, recognition, and treatment of altitude-
related illnesses should also be provided (Bartsch et al., 2004;
Maggiorini, 2010). If the use of acetazolamide during an altitude
sojourn is planned, patients should be asked about allergies and
FIG. 2. Mandibular advancement device. Monobloc device
used for OSA therapy. Snapped onto the teeth during the
night, this custom-fitted device holds the mandible in a
protruded position thereby preventing upper airway occlu-
sion with obstructive sleep apnea. A mandibular advance-
ment device may be an alternative to CPAP therapy in
frequent altitude travelers. Adapted from Bloch et al. (2000).
Table 1. Recommendations to Patients
With Obstructive Sleep Apnea Syndrome
Traveling to Altitude
Pre-travel considerations and evaluation
 Consider available time until departure, duration of travel,
destination, sleeping altitude, available infrastructure.
 Evaluate proper control of OSA by assessing symptoms
and by analyzing CPAP device memory; perform sleep
study and autoCPAP titration if deemed appropriate.
 Check CPAP equipment, proper mask fit, get electrical
cable connections, supplementary batteries and humidifier
if desired; CPAP may be operated in auto-adjusting or in
fixed pressure mode at the level effective at low altitude.
 Inform patients about mandibular advancement devices, a
treatment not requiring electrical power. They should be
custom-fitted and optimally adjusted to control breathing
disturbances which may take several weeks.
 Assess concomitant diseases and associated risks at
altitude and assure proper treatment; sufficient medication
should be available during travel.
 Inform patients about high altitude related illnesses.
Measures during stay at altitude
 Encourage patients to follow general recommendations
regarding sleep hygiene and prevention of high altitude
related illnesses.
 Encourage the use of CPAP or mandibular advancement
device at altitude.
 Consider prescribing acetazolamide (2–3 · 250 mg per day)
to be used in combination with CPAP or a mandibular
advancement device, in particular in patients traveling to
high or very high altitude and in those with concomitant
cardiovascular disease.
 Prescribe acetazolamide (2–3 · 250 mg per day) in patients
unable to use CPAP or a mandibular advancement device.
OBSTRUCTIVE SLEEP APNEA AT ALTITUDE 305
previous use of acetazolamide. A short trial of the drug at home
might be useful to get some experience, including with potential
unpleasant effects (bad taste, paresthesias).
During the pre-travel consultation, effectiveness of OSA
treatment, CPAP adherence, and any related problems should
be assessed. Patients should be asked about residual sleepi-
ness, unrefreshing sleep, and other symptoms suggesting in-
complete control of sleep apnea. Application of the CPAP
equipment in the office may identify an imperfect mask fit,
leaks, and skin lesions that should be taken care of. Patterns of
CPAP use and the AHI recorded in the internal memory of the
CPAP device during home therapy should be downloaded to
assess effectiveness of treatment (Ueno et al., 2010). Depend-
ing on the results, further evaluations including a sleep study
on CPAP should be considered. In patients on fixed pressure
CPAP, a 1–2 week autoCPAP titration period might help to
determine the current effective mask pressure. In the absence
of further scientific studies, it seems that autoCPAP works at
altitude (at least with the one device used in the cited study)
and might have the advantages over a fixed CPAP setting by
continuously adjusting mask pressure according to the actual
needs of the patient (Latshang et al., 2010). Virtually all
modern CPAP devices can be operated at altitude, but man-
ufacturer’s documentation should be studied (according to
the manufacturer’s specification verified at the time of man-
uscript preparation, the most recent CPAP devices from Re-
sMed, Philips Respironics, Breas, Weinmann, and Covidien
incorporate altitude adjustment). Patients planning to use
CPAP during travel should be made aware that an extension
cord and adapters to connect the device to the power outlet
might be required when traveling to foreign countries. CPAP
devices can also be operated from the 12 V electrical circuit of
a car or from portable 12 V batteries (which requires an in-
verter for some CPAP devices). However, the weight of bat-
teries and the need for recharging are drawbacks. The use
of a CPAP device with a humidifier should be considered to
enhance comfort in dry altitude environments, although this
increases power consumption and equipment weight. In pa-
tients with chronic rhinitis, nasal decongestants or topical
steroids might be prescribed (Kohler et al., 2009). In regular
altitude travelers with OSA, analysis of data stored in the
CPAP device during use at altitude with pulse oximetry in-
terfaced to the CPAP device might help to assess the control of
sleep apnea and requirements for treatment adjustments
during subsequent altitude sojourns.
For patients frequently traveling to altitude on treks away
from electricity and who have sufficient time to establish this
treatment, a custom-fitted MAD (Fig. 2) might be prescribed.
MAD treatment generally requires a minimum of 6–8 upper
and lower teeth (although cases of MAD therapy in edentu-
lous patients have been reported) and absence of periodontal
disease and temporomandibular joint pain. A pre-evaluation
and subsequent adaptation of a MAD by a dentist with special
expertise in this field is strongly recommended. MAD therapy
usually requires a preparation during several months and is
therefore not an option for patients immediately departing to
altitude (Bloch et al., 2003; Randerath et al., 2011).
In patients with severe OSA and cardiovascular or pul-
monary co-morbidity, supplemental oxygen applied into
the CPAP tubing might be advisable and will reverse the
adverse effects of being at altitude. The indication has to
be assessed individually according to recommendations for
the underlying disease (Luks and Swenson, 2007). Appro-
priate infrastructure has to be available and the oxygen
dose has to be titrated according to the individual needs.
Monitoring of pulse oximetry might be advisable. In patients
with COPD, restrictive chest-wall or lung disease, or with
neuromuscular disease, ventilatory stimulation by acet-
azolamide might impose an excessive load on respiratory
muscles. It is therefore not generally recommended in these
conditions at altitude.
Recommended OSA Treatment During
Altitude Sojourns
OSA patents living at lowlands and sleeping at an altitude
> 1600 m without treatment are likely to experience pro-
nounced hypoxemia, aggravated breathing disturbances, ele-
vated blood pressure, and vigilance impairment during
daytime (Nussbaumer-Ochsner et al., 2010). Patients should try
to have the lowest sleeping altitude possible and be encouraged
to continue using their CPAP therapy if feasible. Both auto-
adjusting and fixed pressure modes are acceptable. The use of a
humidifier might enhance comfort. As an alternative to CPAP,
patients might use a custom-fitted and optimally adjusted
MAD. General recommendations regarding prevention of high
altitude-related illnesses, including a moderate ascent rate,
avoidance of overexertion should be respected (Nussbaumer-
Ochsner and Bloch, 2007). Depending on the sleeping altitude,
severity of OSA, age, and co-morbidities, the use of acetazol-
amide might be advisable in combination with CPAP (Lat-
shang et al., 2010) or a MAD. In healthy subjects, acetazolamide
at a dose of 2· 125 mg per day is sufficient to prevent acute
mountain sickness. However, in OSA patients, a higher dose of
2· 250 mg or 250 mg in the morning and 500 mg in the evening
is recommended to treat sleep apnea at altitudes (Latshang
et al., 2010). In settings where CPAP therapy is not feasible,
OSA patients may benefit from acetazolamide alone since it is
better than no treatment at all and mitigates hypoxemia and
sleep-related breathing disturbances and improves subjective
well-being at altitude (Nussbaumer-Ochsner et al., 2011).
A summary on pre-travel assessment and treatment of OSA
patients at altitude is provided in Table 1. The proposed
measures should allow patients to enjoy a refreshing sleep
and wonderful daytime experiences in the mountains despite
their OSA.
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